Get the Weekly Intelligence Brief — top committee picks every Sunday.
MRK · NYSE · STOCK

Merck & Co. (MRK) Stock Analysis

Healthcare Updated October 10, 2026
$145.57
52W $82.01 – $156.92
50/100
$359.61B
115.6
0.22
AI Committee Verdict
Watch
50/100
Conviction: Contested · 60% agreement · 5 analysts
+7.8%
-22.6%
0.35:1
Contested

Is MRK Bullish or Bearish?

Mixed. Innellis AI committee rates Merck & Co. (MRK) Watch with a composite score of 50/100 , based on 5 analysts with 60% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +10.02 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -9.98 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 111.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 2.9% pays you to wait — Value
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • P/E of 111.0 is expensive by classic value standards — Value
  • Price-to-book of 5.0x prices in significant intangible value — Value
  • EPS declining -80.7% YoY despite any revenue growth — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
50/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 95%
of 192 Healthcare peers
Value Analyst bearish
25 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 2.9% pays you to wait
− P/E of 111.0 is expensive by classic value standards
Growth Analyst neutral
56 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -80.7% YoY despite any revenue growth
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
55 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 50.9 to 50.0.

Analyst-level changes:
  • News Analyst: score 60->55 (-4).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
53.5
Neutral
MACD Histogram
-0.688
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$112.75
Resistance
$156.90
Bollinger %B
0.48
Inside Bands
Price vs Moving Averages
EMA 9
$144.13 Above
EMA 21
$145.06 Above
EMA 50
$142.16 Above
EMA 200
$125.06 Above

Fundamental Analysis

Valuation
33
Growth
65
Profitability
81
Financial Health
52
Cash Flow
70
Valuation
P/E Ratio 115.6×
P/B Ratio 8.58×
PEG Ratio -1.43
Dividend Yield 2.34%
52W High $156.92
52W Low $82.01
Quality & Growth
ROE 3469.9%
ROA 1333.7%
Gross Margin 7537.6%
Operating Margin 1665.1%
Revenue Growth YoY —
Debt / Equity 1.29
AI Fundamental Assessment
P/E ratio of 115.6 (rich relative to a 15-40x range); Price-to-book of 8.6x; PEG ratio of -1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 34.7%; Return on assets of 13.3%; Net margin of 4.8%; Gross margin of 75.4%; Current ratio of 1.32 (tight short-term liquidity); Debt-to-equity of 1.29; Free cash flow per share is positive (6.50); Most recent quarter beat estimates by 52.3%; 5 consecutive earnings beats; EPS growth accelerating (-161.2% -> +89.8% QoQ); Average YoY EPS growth of -105.9%; Analyst estimates falling over recent quarters
Get the Full MRK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime